GLP-1s, POTS, and hair loss: what's actually causing it?

What's this video probably claiming?

Melissa is almost certainly standing in front of her camera listing off a stack of conditions and medications, trying to figure out which one is wrecking her hair. The suspects she's named, GLP-1 receptor agonists, POTS (postural orthostatic tachycardia syndrome), migraine medications, and possibly a hormonal backdrop, are all legitimate targets. This kind of video is extremely common in the GLP-1 community right now: someone loses meaningful weight, notices their hair shedding in clumps three to six months later, and starts pointing fingers. The frustration is real. So is the confusion. What's less certain is whether she or her commenters are applying any kind of clinical framework to sort out which variable is actually doing the damage, or whether they're just crowdsourcing anxiety.

What does the science actually show?

Let's take these one at a time. GLP-1 agonists like semaglutide and tirzepatide are strongly associated with telogen effluvium, the stress-induced hair shedding that follows rapid weight loss. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), roughly 5.7% of tirzepatide participants reported alopecia versus 1% on placebo. The mechanism isn't the drug itself; it's the caloric deficit and physiological stress. POTS independently disrupts blood flow and autonomic regulation, and chronic sympathetic activation has been theorized to accelerate hair cycling, though direct human trial data here is thin. Migraine medications are a mixed bag: valproate and topiramate both carry hair loss as documented adverse effects (valproate in particular, per the 2004 FDA labeling update). Beta-blockers used for POTS, like propranolol, are also on the confirmed hair-loss list.

Where does the social media noise diverge from clinical reality?

The noise says pick one culprit. Clinical reality says it's almost certainly additive. Telogen effluvium from rapid weight loss typically peaks at three to six months post-trigger (Harrison and Sinclair, 2002, Clinical and Experimental Dermatology), which means if someone started a GLP-1 in January and lost 15% of body weight by April, they're going to be shedding hard by summer regardless of what else is on their chart. Layering a POTS diagnosis, which often involves both sympathetic dysregulation and nutritional absorption issues, onto an already nutritionally stressed scalp makes the situation worse. And if propranolol or topiramate is in the mix, you're stacking confirmed follicular suppressants. What TikTok almost never mentions: ferritin. A serum ferritin below 30 ng/mL is independently associated with telogen effluvium (Rushton et al., 1990, Clinical and Experimental Dermatology), and aggressive GLP-1-driven caloric restriction can drive iron stores down fast.

What should you actually know?

If you're on a GLP-1, losing weight quickly, and your hair is falling out, the first thing your doctor should check is not which drug to blame. It's a panel: ferritin, zinc, thyroid (TSH plus free T4), and a complete metabolic panel. These are the nutritional dominoes that fall during aggressive caloric restriction, and they're treatable. The hair loss from telogen effluvium caused by weight loss is almost always self-limiting, meaning it typically resolves within six to twelve months if the nutritional deficiencies are corrected and weight stabilizes. What's not self-limiting is the pattern that develops when multiple overlapping causes go unaddressed for years. POTS patients in particular deserve a genuine cardiology and neurology workup before anyone attributes all symptoms to a single medication. And anyone taking valproate or topiramate for migraines should have an explicit conversation with their neurologist about hair loss risk and whether alternative prophylactics are appropriate.